Clinical Trial

The Study of the Phenotype of Hereditary Xerocytosis

Study acronym: EPIOX
Recruiting
View on ClinicalTrials.gov →
Summary
Hereditary xerocytosis is a dominant red blood cell membrane disorder characterized by an increased leakage of potassium from the interior to the exterior of the red blood cell membrane, leading to water loss, red cell dehydration, and chronic hemolysis. In 90% of cases, it is associated with heterozygous gain-of-function mutations in PIEZO1, a gene that encodes a mechanotransducer responsible for converting mechanical stimuli into biological signals. The remaining 10% of cases are linked to mutations in the GARDOS channel gene.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-03-18.
Status change: Not Yet Recruiting → Recruiting 2025-04-29
Trial Details
NCT Number NCT06892171
Lead Sponsor Centre Hospitalier Universitaire, Amiens
Collaborators: Kremlin-Bicetre Hospital, Paris
Conditions Xerocytosis, Phenotype, Genotype
Enrollment 20 participants
Start Date 2025-03-01
Primary Completion 2028-03 (estimated)
Study Completion 2028-03 (estimated)
Updated on ClinicalTrials.gov 2025-04-30